Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 5, 2014, Pages 473-476

  Ke, A B ^a   Zamek Gliszczynski, M J ^a   Higgins, J W ^a   Hall, S D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; ITRACONAZOLE; KETOCONAZOLE;

DRUG INTERACTION; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GOLD STANDARD; HUMAN; LOADING DRUG DOSE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

CLARITHROMYCIN; CYTOCHROME P-450 CYP3A; DATABASES, FACTUAL; DRUG DESIGN; DRUG INTERACTIONS; ENZYME INHIBITORS; EUROPE; HUMANS; ITRACONAZOLE; KETOCONAZOLE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84899022587     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.41     Document Type: Review

References (10)

1. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations 〈http://www.fda.gov/ downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362. pdf〉 (February 2012).
2. European Medicines Agency. Guidance on the investigations of drug interactions. 〈http://www. ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2012/07/WC500129606.pdf〉.
3. Han, B., Mao, J., Chien, J.Y. & Hall, S.D. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetics models on prediction of CYP3A inhibition by ketoconazole. Drug Metab. Dispos. 41, 1329-1328 (2013).
4. US Food and Drug Administration, Center for Drug Evaluation and Research. Clinical Pharmacology Review NDA 22-512, Dabigatran 〈http://www. accessdata.fda.gov/drugsatfda- docs/nda/2010/022512Orig1s000ClinPhar mR-Corrrected%203.11.2011.pdf〉 (2011).
5. Quinney, S.K., Zhang, X., Lucksiri, A., Gorski, J.C., Li, L. & Hall, S.D. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug. Metab. Dispos. 38, 241-248 (2010).
6. US Food and Drug Administration. Biaxin XL Filmtab (clarithromycin extended-release tablets) [product label] 〈http://www.accessdata.fda.gov/ drugsatfda-docs/label/2013/050775s020lbl. pdf〉(2013).
7. US Food and Drug Administration. Sporanox (itraconazole) oral solution [product label] 〈http://www.accessdata.fda.gov/drugsatfda- docs/label/2012/020657s027lbl.pdf〉 (2012).
8. Templeton, I.E. et al. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin. Pharmacol. Ther. 83, 77-85 (2008).
9. Templeton, I., Peng, C.C., Thummel, K.E., Davis, C., Kunze, K.L. & Isoherranen, N. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin. Pharmacol. Ther. 88, 499-505 (2010).
10. Gertz, M., Houston, J.B. & Galetin, A. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab. Dispos. 39, 1633-1642 (2011).